Adding a lower cutoff value for CA19-9 may identify additional high-risk cases of pancreatic cancer

To keep the early clinical trial enterprise in the U.S., HHS pledges to simplify regulatory requirements

HHS earlier this week rolled out a cluster of initiatives related to simplifying clinical trials, presenting these measures as a government-wide effort to maintain America’s leadership in early-stage drug development.

Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise

When Robert Mayer was only a few years out of residency, in the 1970s, he signed on as an investigator of the NCI-supported Gastrointestinal Tumor Study Group, which conducted research into colorectal, gastric, and pancreatic cancers.

MD Anderson’s Vincent Bernard receives Project Purple’s Research Recovery Grant for pancreatic cancer research

Project Purple has awarded a $375,000 Research Recovery Grant to researchers at the University of Texas MD Anderson Cancer Center to continue critical pancreatic cancer research.

June 26, 2026

Vol.52 No.25

Clinical Roundup

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

Sigvotatug vedotin, an integrin beta-6 directed antibody-drug conjugate, did not show a statistically significant improvement in the primary endpoint of overall survival, compared to docetaxel, according to the results of the phase III SigVie-002 study (previously known as Be6A Lung-01).

June 26, 2026

Vol.52 No.25

Clinical Roundup

TAMP procedure shows 52% reduction in pancreatic tumor metabolic activity, Moffitt case study shows

Researchers at Moffitt Cancer Center have published a case study highlighting the potential optimization of the TAMP, or trans-arterial micro-perfusion, procedure with RenovoCath to deliver intra-arterial gemcitabine (a commonly used chemotherapy) directly near a tumor (rather than traditional systemic IV administration) in a patient with locally advanced pancreatic cancer.

June 26, 2026

Vol.52 No.25

Clinical Roundup

Sylvester researchers discover method of disrupting inflammatory network that helps pancreatic cancer resist treatment

Blocking IL1RAP, a receptor that sits at a key control point in inflammatory signaling, can disrupt the tumor-driven inflammatory network that helps pancreatic cancer resist treatment, according to a study led by researchers at Sylvester Comprehensive Cancer Center.

June 26, 2026

Vol.52 No.25

Adding a lower cutoff value for CA19-9 may identify additional high-risk cases of pancreatic cancer

YOU MAY BE INTERESTED IN

To keep the early clinical trial enterprise in the U.S., HHS pledges to simplify regulatory requirements

Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise

MD Anderson’s Vincent Bernard receives Project Purple’s Research Recovery Grant for pancreatic cancer research

Sigvotatug vedotin misses OS primary endpoint vs. docetaxel in phase III trial in previously treated metastatic non-squamous NSCLC

TAMP procedure shows 52% reduction in pancreatic tumor metabolic activity, Moffitt case study shows

Sylvester researchers discover method of disrupting inflammatory network that helps pancreatic cancer resist treatment

Renew today!

Subscriber content

Never miss an issue!

Login